Zentalis Pharmaceuticals, Inc.
ZNTL
$1.63
-$0.12-6.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 26.87M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 26.87M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 26.87M | -- | -- |
| SG&A Expenses | 7.30M | 10.58M | 40.01M | 14.61M | 16.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.91M | 37.83M | 72.98M | 51.43M | 65.15M |
| Operating Income | -34.91M | -37.83M | -46.11M | -51.43M | -65.15M |
| Income Before Tax | -26.87M | -48.28M | -47.68M | -40.19M | -88.01M |
| Income Tax Expenses | -- | -- | -205.00K | -27.00K | 266.00K |
| Earnings from Continuing Operations | -26.87M | -48.28M | -47.47M | -40.16M | -88.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 0.00 | -- | -- |
| Net Income | -26.87M | -48.28M | -47.47M | -40.16M | -88.28M |
| EBIT | -34.91M | -37.83M | -46.11M | -51.43M | -65.15M |
| EBITDA | -34.75M | -37.57M | -45.80M | -51.11M | -64.82M |
| EPS Basic | -0.37 | -0.67 | -0.67 | -0.56 | -1.24 |
| Normalized Basic EPS | -0.22 | -0.33 | -0.63 | -0.35 | -0.57 |
| EPS Diluted | -0.37 | -0.67 | -0.67 | -0.56 | -1.24 |
| Normalized Diluted EPS | -0.22 | -0.33 | -0.63 | -0.35 | -0.57 |
| Average Basic Shares Outstanding | 71.99M | 71.68M | 71.27M | 71.11M | 71.04M |
| Average Diluted Shares Outstanding | 71.99M | 71.68M | 71.27M | 71.11M | 71.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |